Daiichi and AZ pull Dato-DXd filing in Europe too
AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
FDA approves flurry of drugs ahead of holiday season
The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
AZ gets EU okay for Tagrisso in early-stage lung cancer
AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU for a form of early-stage lung cancer.
Sanofi takes SK Bio-partnered pneumococcal shot into phase 3
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
PBM reform dropped in Congress' funding package
Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Welcome to the Bacteriophage Therapy Summit!
Combating Antibiotic Resistance with Effective & Sustainable Phage-Based Therapies
Biotech Showcase marking 17 years of innovation and opportun...
Biotech Showcase is a cornerstone of the life science industry, with a 17-year history of connecting private and micro- to mid-cap biotech companies with top-tier investors and biopharmaceu